CD274 and classic Hodgkin lymphoma: Furthermore, among all the cHL patients, 34 patients were refractory to PD-(L)1 blockade (defined as disease progressing during treatment or within 3 months after the last dose), 28 patients received PD-1 blockade as their latest therapy, and 21 patients received at least 2 lines of PD-(L)1 blockades (Table 1).